Caribou Biosciences, Inc.
5 clinical trials · Sponsor
◉ Watch Caribou Biosciences, Inc.
| Record | Firm | Date |
|---|---|---|
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) (NCT06752876) | Caribou Biosciences, Inc. | 2027-12-01 |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT06128044) | Caribou Biosciences, Inc. | 2024-02-08 |
| CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (NCT05722418) | Caribou Biosciences, Inc. | 2023-02-06 |
| Long-Term Follow-up Study (NCT05332054) | Caribou Biosciences, Inc. | 2022-03-16 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (NCT04637763) | Caribou Biosciences, Inc. | 2021-05-26 |
Track Caribou Biosciences, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.